top of page
logo hyalivia

AQUALIPS

The first lip skinbooster with NAD+ and dual molecular weight HA for superior hydration, repair, and longevity.

HYALIVIA AQUALIPS SIRT1 is a revolutionary lip skinbooster designed to deeply hydrate, protect, and regenerate lip tissue while improving lip elasticity, texture, and natural volume.

WHY
IT'S UNIQUE

  • The first lip booster scientifically formulated with NAD+ to enhance Sirtuin 1 activation.

 

  • Dual molecular weight hyaluronic acid (HA) provides deep and surface-level hydration for lasting results.

 

  • MDR CE-certified formulation ensures safety and effectivenes.

Copia di HYA MINI  (5)
nikolfandi98_22255_Cinematic_ultra-realistic_frontal_close-up_42c7163b-2e95-4d8c-a9b4-a98e

How HYALIVIA AQUALIPS is Different from Traditional Skinboosters

Traditional lip boosters primarily add volume by injecting cross-linked hyaluronic acid, but the effects are temporary as the HA breaks down over time.

 

AQUALIPS goes beyond simple plumping with a dual-action approach:

  • Long-Lasting Hydration: 48 mg Linear Sodium Hyaluronate i locks in moisture for extended hydration, keeping lips plump and smooth longer.

  • Collagen Stimulation: Proline & Glycine boosts collagen production, enhancing lip firmness and structure for lasting rejuvenation.

  • Cellular Repair & Anti-Aging: NAD+ activates Sirtuin 1, supporting cellular repair and reducing fine lines, offering long-term skin health.

Traditional fillers only replace lost volume, but Our Innovative  Skinbooster HYALIVIA AQUALIPS help the skin restore itself from within.

With the power of NAD+, Proline, and Glycine, HYALIVIA AQUALIPS sets a new standard in aesthetic treatments by offering hydration, volume, and structural improvement all in one product. 

nikolfandi98_22255_Ultra-realistic_macro_shot_of_red_blood_an_b353ce1d-64b5-4fde-ace3-992a
Brochure Aqualips 2_edited

Scientific Approach

The Power of NAD+

NAD+

A powerhouse ingredient that activates Sirtuin 1, NAD+ enhances cellular repair, combats oxidative stress, and promotes skin longevity.

 

It improves skin hydration, elasticity, and helps reduce fine lines, giving lips a smoother, rejuvenated look.

SIRT1

SIRT1 activation represents the pinnacle of advanced lip rejuvenation science.

 

When powered by Nicotinamide Adenine Dinucleotide the NAD+, this "longevity enzyme" orchestrates a comprehensive cellular renewal process that traditional lip treatments simply cannot match.

 

By enhancing collagen production, optimizing cellular metabolism, and strengthening the lip's protective barriers, SIRT1 delivers what aesthetic professionals and patients truly seek: lips that look naturally fuller, smoother, and more youthful through genuine tissue regeneration rather than mere temporary filling.

Key Benefits

  • REVOLUTIONARY HYDRATION: Dual molecular weight hyaluronic acid delivers both deep and surface moisture for lasting softness.

  • CELLULAR REJUVENATION: Exclusive NAD+ technology activates SIRT1 to repair and regenerate lips tissue at the cellular level.

  • NATURAL VOLUME ENHANCEMENT: Creates fuller, plumper lips through tissue regeneration.

  • ANTI-AGING PROTECTION: Strengthens the lip barrier function while reducing fine lines and preventing premature aging.

  • LONG-LASTING RESULTS: Superior formulation provides sustained benefits with fewer treatment sessions.

The Science Behind 

The Role of NAD+

NAD+ is a crucial cellular coenzyme that powers Hyalivia AcquaLips SIRT1's exceptional results.

 

This vital molecule naturally decreases with age, contributing to lip thinning and fine lines.

 

What sets our formula apart is its ability to deliver bioavailable NAD+ directly to lip tissue, activating SIRT1 the "longevity protein" that triggers cellular repair, protection against oxidative damage, and enhanced collagen production.

This scientific breakthrough results in naturally fuller, more youthful lips through genuine tissue regeneration rather than temporary filling. Total Dermal Filler Face Lift for youthful, smooth, and lifted skin.

PHOTO-2025-09-07-19-57-29 2
bottom of page